Boston Scientific Corporation
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.
Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.
Top-decile sponsor footprint
Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 1 of 6
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269
Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)
NCT07502599
Respiration Measured Via End-tidal CO2 and Spirometry Study (RESPI)
NCT07537478
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
NCT06894498
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
NCT07035431
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
NCT07015424
RESCUE: Discontinuation of GLP-1
NCT07190794
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT07190807
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
NCT06735534
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262
POLARx Post Approval Study (POLARx PAS)
NCT06170606
A DirEct to PatieNt Study in Chronic Pain
NCT05515341
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT05303467
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Patient Retrospective Outcomes (PRO)
NCT01550575
SpaceIT Hydrogel System for Perirectal Spacing
NCT06451614
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
NCT06492174
SIMPLAAFY Clinical Trial
NCT06521463
ADVENT Post Approval Study
NCT06431815
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
NCT06192758
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
NCT06096337
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
NCT04905069
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
NCT04798768
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
NCT04647253
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
NCT04790344
Paresthesia-Free Fast-Acting Subperception (FAST) Study
NCT04618471
CHAMPION-AF Clinical Trial
NCT04394546
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
NCT04192591
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation
NCT04147884
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453
RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
NCT03053141
ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study
NCT06526546
Obsidio™ Conformable Embolic Registry
NCT06170619
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
NCT06132568
SpyGlass Surgical Study
NCT05822635
HEAL-LAA Clinical Trial
NCT05809596
MANTIS Endoscopic Clipping Study
NCT05653843
A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
NCT05443594
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
NCT05312970
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
NCT05233098
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 3 | 33 |
| Phase 4 | 26 |
Therapeutic Areas
Where Boston Scientific Corporation enrollment is open (later-stage tilt)
22 recruiting of 280 indexed (8% open); 207 completed (74%).
Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).
Top condition: Coronary Artery Disease (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boston Scientific Corporation: open-pipeline peers nationwide
Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
- United Therapeutics · 8% recruiting · 63 trials
Related
What to do with this Boston Scientific Corporation page
280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.
- 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets.Report a data error.